Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tumor Infiltrating Lymphocyte (TIL) Therapy for the Treatment of Advanced Solid Tumors

NCT06334783 is registered in ClinicalTrials.gov with Hervor Therapeutics as lead sponsor.

NCT NCT06334783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06334783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tumor Infiltrating Lymphocyte (TIL) Therapy for the Treatment of Advanced Solid Tumors
Lead sponsor
Hervor Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
May 30, 2023
Completion date
July 31, 2025
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor